Patents Assigned to Conforma Therapeutics Corporation
  • Patent number: 8093229
    Abstract: Alkynyl pyrrolo [2,3-d] pyrimidines of Formula I are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders. Methods of synthesis and use of such compounds are also described and claimed.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: January 10, 2012
    Assignee: Conforma Therapeutics Corporation
    Inventors: Srinivas Rao Kasibhatla, Marco Antonio Biamonte, Jiandong Shi, Marcus F. Boehm
  • Patent number: 7579462
    Abstract: Efficient chemical processes for preparing high yields, purities, and different polymorphic forms of 17-allyl amino geldanamycin (17-AAG) and other ansamycins are described and claimed.
    Type: Grant
    Filed: September 18, 2002
    Date of Patent: August 25, 2009
    Assignee: Conforma Therapeutics Corporation
    Inventors: Lin Zhang, Marcus F. Boehm, Siead Zegar
  • Patent number: 7553979
    Abstract: Zearalanol compounds are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various disorders. Methods of synthesis and use of such compounds are also described and claimed.
    Type: Grant
    Filed: November 8, 2002
    Date of Patent: June 30, 2009
    Assignee: Conforma Therapeutics Corporation
    Inventors: Srinivas R. Kasibhatla, Jean-Yves Le Brazidec, Sean Konrad McHugh, Marcus F. Boehm
  • Patent number: 7544672
    Abstract: Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders. Methods of synthesis and use of such compounds are also described and claimed.
    Type: Grant
    Filed: March 29, 2006
    Date of Patent: June 9, 2009
    Assignee: Conforma Therapeutics Corporation
    Inventors: Srinivas Rao Kasibhatla, Marco Antonio Biamonte, Jiandong Shi, Marcus F. Boehm
  • Patent number: 7465718
    Abstract: Ansamycins and methods of preparing and using the same are described. At least some of these ansamycins exhibit one or more of improved aqueous formulation ability, chemical stability, and bioavailability. Some of the derivatives described are dimers. These and others described can include one or more solubilizing groups that have expected merit in rendering the overall compounds useful as drugs and prodrugs.
    Type: Grant
    Filed: February 10, 2003
    Date of Patent: December 16, 2008
    Assignee: Conforma Therapeutics Corporation
    Inventors: Lin Zhang, Jean-Yves Le Brazidec, Lawrence C. Fritz, Francis J. Burrows, Marcus F. Boehm, Junhua Fan, Sean Konrad McHugh
  • Publication number: 20070253896
    Abstract: The invention relates in general to 7,9-dihydro-purin-8-one and related compounds that show broad utility, e.g., in inhibiting heat shock protein 90 (HSP90) to thereby treat or prevent HSP90-mediated diseases.
    Type: Application
    Filed: February 5, 2007
    Publication date: November 1, 2007
    Applicant: CONFORMA THERAPEUTICS CORPORATION
    Inventors: Jean-Yves Le Brazidec, Srinivas Kasibhatla, David Hurst, Marcus Boehm
  • Publication number: 20070185064
    Abstract: 2-Aminopurine analogs are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Method of synthesis and use of such compounds are also described and claimed.
    Type: Application
    Filed: September 12, 2006
    Publication date: August 9, 2007
    Applicant: Conforma Therapeutics Corporation
    Inventors: Srinivas Kasibhatla, Kevin Hong, Marcus Boehm, Marco Biamonte, Lin Zhang
  • Publication number: 20070173483
    Abstract: Pyrrolopyrimidines and related analogs are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Methods of synthesis and use of such compounds are also described and claimed.
    Type: Application
    Filed: September 12, 2006
    Publication date: July 26, 2007
    Applicant: Conforma Therapeutics Corporation
    Inventors: Srinivas Kasibhatla, Jiandong Shi, Jean-Yves Le Brazidec, Marco Biamonte, Kevin Hong, Marcus Boehm
  • Patent number: 7241890
    Abstract: Novel purine compounds of Formula I. and tautomers, pharmaceutically acceptable salts, and prodrugs thereof, wherein X is S, S(O), or S(O)2; and O is selected from alkyl, cycloalkyl, arylalkyl, aryl, heteroaryl, and heterocyclic, all optionally substituted, are described, as are pharmaceutical compositions comprising the same, complexes comprising the same, e.g., HSP90 complexes, and methods of using the same.
    Type: Grant
    Filed: October 30, 2002
    Date of Patent: July 10, 2007
    Assignee: Conforma Therapeutics Corporation
    Inventors: Srinivas Rao Kasibhatla, Kevin Hong, Lin Zhang, Marco Antonio Biamonte, Marcus F. Boehm, Jiandong Shi, Junhua Fan
  • Publication number: 20070129334
    Abstract: Novel purine compounds and tautomers and pharmaceutically acceptable salts thereof are described, as are pharmaceutical compositions comprising the same, complexes comprising the same, e.g., HSP90 complexes, and methods of using the same. Methods of using the novel purine compounds of the invention, and tautomers and pharmaceutically acceptable salts thereof, include their use in inhibiting heat shock protein 90's (HSP90's) to thereby treat or prevent HSP90-dependent diseases, e.g., proliferative disorders such as breast cancer.
    Type: Application
    Filed: December 18, 2006
    Publication date: June 7, 2007
    Applicant: CONFORMA THERAPEUTICS CORPORATION
    Inventors: Srinivas Kasibhatla, Lin Zhang, Marco Biamonte, Marcus Boehm, Junhua Fan, Jiandong Shi, Kevin Hong
  • Publication number: 20070129342
    Abstract: Provided are pharmaceutical compositions containing an oil phase and an aqueous phase, the oil phase including an ansamycin and less than 2% w/w oleic acid, wherein the ansamycin is geldanamycin, 17-aminogeldanamycin, 17-allyalamino-17-demethoxy-geldanamycin, compound 563, or compound 237 having the structures below, or a salt of any one of the aforementioned ansamycins
    Type: Application
    Filed: November 30, 2006
    Publication date: June 7, 2007
    Applicant: CONFORMA THERAPEUTICS CORPORATION
    Inventors: Robert Mansfield, Edgar Ulm
  • Publication number: 20070111997
    Abstract: Triazolopyrimidines and related compounds are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Method of synthesis and use of such compounds are also described and claimed.
    Type: Application
    Filed: September 29, 2006
    Publication date: May 17, 2007
    Applicant: Conforma Therapeutics Corporation
    Inventors: Srinivas Kasibhatla, Kevin Hong, Marcus Boehm
  • Publication number: 20070111996
    Abstract: Pyrazolopyrimidines and related analogs are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Method of synthesis and use of such compounds are also described and claimed.
    Type: Application
    Filed: September 29, 2006
    Publication date: May 17, 2007
    Applicant: Conforma Therapeutics Corporation
    Inventors: Srinivas Kasibhatla, Marco Biamonte, Kevin Hong, David Hurst, Marcus Boehm
  • Publication number: 20070105874
    Abstract: The present invention provides a method of treating an individual having an HSP90 mediated disorder comprising administering to said individual a pharmaceutical composition comprising a pharmaceutically effective amount of a synthetic heterocyclic HSP90 inhibitor, wherein the activity of the HSP90 inhibitor is substantially independent of multi drug resistance. In one embodiment, the activity of the HSP90 inhibitor is substantially independent of P-gp and MRP expression.
    Type: Application
    Filed: September 25, 2006
    Publication date: May 10, 2007
    Applicant: Conforma Therapeutics Corporation
    Inventors: Hong Zhang, Francis Burrows
  • Patent number: 7148228
    Abstract: A compound represented by Formula I, or a polymorph, ester, tautomer, enantiomer, pharmaceutically acceptable salt or prodrug thereof: wherein: R1 is halogen, —OR1, —SR11 or lower alkyl; R2 is —NHR8; R3 is selected from the group consisting of hydrogen, halogen, —SR8, —OR8, —CN, —C(O)R9, —CO2H, —NO2, —NR8R10, lower alkyl, lower alkenyl, lower alkynyl, lower perhaloalkyl, aryl, heteroaryl, alicyclic and heterocyclic, all optionally substituted, wherein: the aryl, heteroaryl, alicyclic and heterocyclic groups are optionally mono-, bi- or tri-cyclic, R4 is —CHR12—, —C(O), —C(S), —S(O)—, or —SO2—; R5 is aryl, heteroaryl, alicyclic, or heterocyclic, wherein the aryl group is substituted with 3 to 5 substituents, the heteroaryl group is substituted with 2 to 5 substituents, the alicyclic group is substituted with 3 to 5 substituents, the heterocyclic group is substituted with 3 to 5 substituents.
    Type: Grant
    Filed: September 20, 2004
    Date of Patent: December 12, 2006
    Assignee: Conforma Therapeutics Corporation
    Inventors: Srinivas Rao Kasibhatla, Marco A. Biamonte, Kevin D. Hong, David Hurst, Marcus F. Boehm
  • Patent number: 7138401
    Abstract: 2-Aminopurine analogs are described and demonstrated or predicted to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents in the treatment and prevention of various HSP90 mediated disorders, e.g., proliferative disorders. Method of synthesis and use of such compounds are also described and claimed.
    Type: Grant
    Filed: September 20, 2004
    Date of Patent: November 21, 2006
    Assignee: Conforma Therapeutics Corporation
    Inventors: Srinivas Rao Kasibhatla, Kevin D. Hong, Marcus F. Boehm, Marco A. Biamonte, Lin Zhang
  • Patent number: 7138402
    Abstract: The present invention provides compounds represented by Formula I.
    Type: Grant
    Filed: September 20, 2004
    Date of Patent: November 21, 2006
    Assignee: Conforma Therapeutics Corporation
    Inventors: Srinivas R. Kasibhatla, Jiandong Shi, Jean-Yves Le Brazidec, Marco A. Biamonte, Kevin D. Hong, Marcus F. Boehm
  • Patent number: 7129244
    Abstract: A compound represented by Formula I, or a polymorph, ester, tautomer, enantiomer, diastereomer, pharmaceutically acceptable salt or prodrug thereof, Wherein R1 is halogen, —OR11, —SR11 or lower alkyl; R2 is —NHR8; R4 is —CHR12—, —C(O)—, —C(S)—, —S(O)— or —S2—; and R5 is aryl, heteroaryl, alicyclic, or heterocyclic, wherein the aryl group is substituted with 4 to 5 substituents, the heteroaryl group is substituted with 3 to 5 substituents, the alicyclic group is substituted with 3 to 5 substituents, and the heterocyclic group is substituted with 3 to 5 substituents.
    Type: Grant
    Filed: September 20, 2004
    Date of Patent: October 31, 2006
    Assignee: Conforma Therapeutics Corporation
    Inventors: Srinivas Rao Kasibhatla, Kevin D. Hong, Marcus F. Boehm
  • Publication number: 20060148776
    Abstract: Drug formulations having emulsifying agents and both medium and long chain triglycerides are described. In preferred embodiments, the long chain triglycerides negate or lessen deleterious central nervous system effects that are caused by medium chain triglycerides.
    Type: Application
    Filed: October 4, 2003
    Publication date: July 6, 2006
    Applicant: Conforma Therapeutics Corporation
    Inventors: Edqar Ulm, Robert Mansfield, Marcus Boehm
  • Publication number: 20050176695
    Abstract: Efficient chemical processes for preparing high yields, purities, and different polymorphic forms of 17-allyl amino geldanamycin (17-AAG) and other ansamycins are described and claimed.
    Type: Application
    Filed: September 18, 2002
    Publication date: August 11, 2005
    Applicant: Conforma Therapeutics Corporation
    Inventors: Lin Zhang, Marcus Boehm, Siead Zegar